Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination

Alberto Cagigi[1], Meng Yu[1], Björn Österberg[1], Julia Svensson[1], Sara Falck-Jones[1], Sindhu Vangeti[1], Eric Åhlberg[1], Lida Azizmohammadi[1], Anna Warnqvist[2], Ryan Falck-Jones[3,4], Pia C Gubisch[1], Mert Ödemis[1], Farangies Ghafoor[1], Mona Eisele[1], Klara Lenart[1], Max Bell[3,4], Niclas Johansson[5,6], Jan Albert[7,8], Jörgen Sälde[9], Deleah Pettie[10,11], Michael Murphy[10,11], Lauren Carter[10,11], Neil P King[10,11], Sebastian Ols[1], Johan Normark[12], Clas Ahlm[12], Mattias Forsell[12], Anna Färnert[5,6], Karin Loré[1*] and Anna Smed-Sörensen[1*]

[1]Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. [2]Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. [3]Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. [4]Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm, Sweden. [5]Division of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Sweden. [6]Department of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden. [7]Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. [8]Clinical Microbiology, Karolinska University Hospital Solna, Stockholm, Sweden. [9]Närakut SLSO, Karolinska University Hospital Solna, Stockholm, Sweden. [10]Department of Biochemistry, University of Washington, Seattle, WA, United States. [11]Institute for Protein Design, University of Washington, Seattle, WA, United States. [12]Section of Infection and Immunology, Department of Clinical Microbiology, Umeå university, Umeå, Sweden. [*]Equal contribution.

Correspondence to: Karin Loré and Anna Smed-Sörensen, Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum J7:30, Karolinska University Hospital, 171 64 Stockholm, Sweden.

E-mail addresses: karin.lore@ki.se; anna.smed.sorensen@ki.se

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Abstract

Understanding the presence and durability of antibodies against SARS-CoV-2 in the airways is required to provide insights on the ability of individuals to neutralize the virus locally and prevent viral spread. Here, we longitudinally assessed both systemic and airway immune responses upon SARS-CoV-2 infection in a clinically well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. In addition, we evaluated how SARS-CoV-2 vaccination influenced the antibody responses in a subset of these individuals during convalescence as compared to naïve individuals. Not only systemic but also airway antibody responses correlated with the degree of COVID-19 disease severity. However, while systemic IgG levels were durable for up to 8 months, airway IgG and IgA had declined significantly within 3 months. After vaccination, there was an increase in both systemic and airway antibodies, in particular IgG, often exceeding the levels found during acute disease. In contrast, naïve individuals showed low airway antibodies after vaccination. In the former COVID-19 patients, airway antibody levels were significantly elevated after the boost vaccination, highlighting the importance of prime and boost vaccination also for previously infected individuals to obtain optimal mucosal protection.

50 **Introduction**

51 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes
52 coronavirus disease 2019 (COVID-19) presents with a wide range of disease severity from
53 asymptomatic to fatal (1, 2). Individuals of advanced age and/or those with comorbidities
54 are overrepresented among patients who develop severe disease (3). However, the majority
55 of SARS-CoV-2 infected individuals experience asymptomatic infection or only mild disease
56 (4).

57

58 Systemic antibodies against the SARS-CoV-2 nucleocapsid (N) and the viral surface
59 glycoprotein spike (S) as well as against the receptor binding domain (RBD) (5, 6) of the S
60 protein have been studied extensively (7-11). Responses against the internal N protein are
61 often readily detectable but their contribution to protection and control of disease is not
62 clear (8, 10). In contrast, antibody responses against S and, in particular, against the RBD
63 result in virus neutralization (12). Responses against the RBD are thus likely necessary for
64 protection from re-infection or prevention of symptomatic disease. However, the presence
65 and durability of antibodies during COVID-19 in the airways is still not well understood.

66 The respiratory tract is the initial site of viral infection and replication. The availability
67 of antibodies at this site could therefore determine the ability to neutralize the virus locally
68 in case of (re-) exposure and prevent viral spread. Generally, antibodies present in the
69 circulation and at local sites are the result of secretion from short-lived plasmablasts and/or
70 terminally differentiated plasma cells in the bone marrow or mucosal sites (13). However,
71 the response to a secondary infection once antibody titers have waned below protective
72 levels mostly relies on the presence of resting antigen-specific memory B cells that are
73 rapidly activated upon antigen re-exposure (13). Whether vaccination against SARS-CoV-2

74 also elicits systemic antibody responses in addition to local antibodies in the airways of
75 individuals who recovered from COVID-19, and via which mechanism, is currently unknown.
76 In this study we present data from a cohort of patients that we have followed since
77 mid-March 2020, which was the start of the pandemic in Sweden. We show longitudinal
78 data on virus-specific systemic and airway antibody and B cell memory responses generated
79 in this clinically well-characterized cohort of individuals with SARS-CoV-2 infection (n=147)
80 ranging from asymptomatic SARS-CoV-2 infection to fatal COVID-19 disease. In addition, we
81 show how subsequent SARS-CoV-2 vaccination during the convalescent phase significantly
82 boosts not only the systemic but also airway antibody responses.
83
84 **Results**
85 **Patient enrollment, assessment of disease severity and timeline**
86 Individuals were sampled longitudinally in blood and airways during acute
87 infection/symptomatic disease and during convalescence (median 3 and 8 months from
88 symptom onset). Donor-matched plasma, peripheral blood mononuclear cells (PBMC),
89 nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected from all patients
90 across disease severities whereas endotracheal aspirates (ETA) were only collected from
91 intubated patients receiving intensive care (Figure 1). Disease severity was assessed daily,
92 using a seven-point scale derived from the respiratory domain of the sequential organ failure
93 assessment (SOFA) score (14, 15), with additional levels for non-admitted and fatal cases
94 (Table 1). Patients were grouped based on peak disease severity, which may differ from
95 disease severity at time of sampling (Table 1 and Figure 1B). In addition, pre-pandemic
96 healthy controls (PPHC) (n=30) as well as individuals with influenza-like symptoms, and
97 possible SARS-CoV-2 exposure, but with negative diagnostic PCR results (PCR-) (n=9) were

98 sampled in the same way and included as controls. Generally, severe patients were sampled
99 later after symptom onset as compared with individuals with mild disease resulting in a large
100 time frame of study inclusion with respect to symptom onset (Table 1 and Figure 1B) (16).
101 For simplicity, the sampling period/study inclusion during ongoing infection and
102 hospitalization (for those hospitalized) is referred to as the "acute" phase. Samples collected
103 at the first follow-up visit during convalescence (range 46-168 days from symptom onset;
104 median 108 days, coefficient of variation 21.56%) are referred to as the "3 months"
105 timepoint whereas those collected at the second follow-up visit (range 187-344 days;
106 median 245 days, coefficient of variation 9.52%) are referred to as the "8 months"
107 timepoint. Time of the first convalescent follow-up sampling from acute sampling ranged 33-
108 159 days; median 90 days, coefficient of variation 24.84% (Table 1).
109
110 **Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during acute**
111 **disease and after recovery**
112 We first assessed systemic IgG and IgA responses against N, S and RBD at the time of study
113 inclusion that ranged between 0-54 days from onset of symptoms; median 16 days for the
114 whole cohort (Table 1). Both IgG and IgA levels against all viral proteins followed the degree
115 of disease severity with increasing levels in patients with mild, moderate and severe disease
116 respectively (Figure 2A). In line with previous reports, IgG against N were the most elevated
117 in patients who had severe disease or a fatal outcome (8, 10). The degree of disease severity
118 also associated with the levels of systemic inflammation as indicated by the levels of C-
119 reactive protein (CRP) in blood and by the neutrophil-lymphocyte ratio (NLR) (Figure 2B).
120 Interestingly, the levels of neutrophils also specifically associated with disease severity
121 (Figure 2D) and with all of the systemic antibody responses during acute disease (Figure 2D

122 and Supplementary figure 1). The levels of IgG during acute disease, and to a lower extent
123 IgA, against all tested antigens, exhibited a positive correlation with the days from onset of
124 symptoms (Supplementary figure 2A). This difference in antibody titers over time might be
125 slightly accentuated by the fact that in our cohort the patients with moderate/severe
126 disease, and even fatal outcome, for whom we initially observed low IgG titers against RBD,
127 had an early study inclusion (on average 13 days from onset of symptoms). In fact, these
128 patients showed significantly higher titers later during the acute phase (on average 19 days)
129 (Supplementary figure 2B-C). Nonetheless, patients with mild disease displayed lower levels
130 of plasma IgG against RBD as compared with more severe patients, also when samples were
131 taken after similar duration of symptoms (Supplementary figure 2D). After 3 months from
132 symptom onset, the IgG levels remained high in the plasma of patients recovering from
133 moderate and severe disease, while the levels had further increased in the individuals who
134 had a mild disease (Figure 3A). However, despite this increase over time, the antibody levels
135 in mild patients never reached the levels observed for moderate and severe patients or for
136 those who had a fatal outcome (Figure 3 and Supplementary figure 3A).
137 The IgG levels had significantly waned from 3 to 8 months in patients who recovered from
138 moderate and severe disease, but the decline was smaller in patients who experienced a
139 mild disease (Figure 3B, Supplementary figure 3 and Supplementary table 1). In contrast to
140 IgG, IgA levels from the acute phase, against all antigens, waned substantially in most
141 patients already after 3 months (Figure 3, Supplementary figure 3 and Supplementary table
142 1). Antibody titers during acute disease correlated with peak disease severity as well as with
143 disease severity at time of sampling (Supplementary figure 4). The correlation between
144 antibody titers and peak disease severity was maintained also when analyzing the antibodies
145 at the 3- and 8-month follow-up visits (Supplementary figure 4) as also observed in another

146 study (17). Two multivariable linear regression models were also used to estimate the effect
147 of disease severity, days from onset of symptoms, age, gender and CCI on the different
148 plasma antibody levels during the acute phase. One unadjusted model and one model
149 adjusted for these parameters were used (Supplementary table 2). The results from these
150 analyses confirmed the relation between antibody titers and severity as well as the relation
151 between antibodies and days from onset of symptoms (Supplementary table 2).
152
153 **Airway IgG and IgA responses and assessment of B cell frequencies in the respiratory tract**
154 We next measured the levels of IgG and IgA in the upper and lower airways and compared
155 with levels in plasma at matched time points. Due to limited respiratory sample volumes, we
156 focused our analyses on IgG and IgA responses against the RBD since these responses are
157 most critical for virus neutralization. We found that RBD-specific antibodies could be
158 detected in nasal swabs (NSW) (Figure 4A) and nasopharyngeal aspirates (NPA) (Figure 4B)
159 during the acute phase across all disease severities (Figure 4A, B and C). In agreement with
160 our observations in plasma, antibody levels in the upper respiratory tract were higher in
161 patients with moderate or severe disease as compared with individuals with mild disease.
162 Both IgG and IgA levels had declined significantly already after 3 months, with IgG declining
163 to almost undetectable levels (Figure 4A- C). RBD antibody levels during acute infection were
164 on average higher in NPA compared to NSW for both IgG and IgA across disease severity
165 (Figure 4A- C) suggesting that antibody titers may increase not only with disease severity but
166 also with sampling at different depths of the upper airways. To address this, we compared
167 the antibody content between donor-matched NSW (peripheral nostril), NPA (upper airway)
168 and ETA (trachea) collected at the same time point during acute disease from intubated
169 patients from whom we had both peripheral, upper and lower airway samples. Interestingly,

170 we still found significantly higher levels of IgA against the RBD in NPA as compared with NSW
171 and ETA (Figure 4D). Furthermore, nasopharyngeal antibody levels (both IgG and IgA)
172 showed a strong correlation with plasma antibody responses (Figure 4E). We also assessed
173 the presence of B cells in the respiratory tract of COVID-19 patients by analyzing the
174 lymphocytes that could be retrieved from NPA and ETA as compared with NPA from three
175 healthy controls (HC). Despite generally obtaining a significantly lower cell yield from NPA as
176 compared with ETA, lymphocyte frequencies did not differ in NPA and ETA from COVID-19
177 patients but both were lower as compared with NPA from HC. Instead, the proportion of B
178 cells in NPA was higher as compared with ETA in COVID-19 patients and similar to NPA from
179 HC (Figure 5A-B).
180
181 **Expansion of SARS-CoV-2-specific memory B cells**
182 As mentioned above, the virus-specific B cell memory pool will be essential to remount a
183 rapid antibody response in the case of re-exposure. To assess the establishment of antigen-
184 specific memory B cells, donor-matched PBMC from acute disease and convalescence were
185 analyzed side-by-side using fluorescently labelled S and RBD probes (18-20). Patients with
186 moderate/severe disease showed the presence of Ig-switched memory B cells specific to S in
187 the acute phase and the memory B cell pool had further expanded after 3 months (ranging
188 from 0.009 to 1.35%; mean 0.42% during convalescence) (Figure 5C-F). Individuals with mild
189 disease showed lower frequencies of S-specific memory B cells during acute disease than the
190 patients with moderate/severe disease. In fact, the frequencies of S-specific memory B cells
191 in the mild patients during the acute phase were not different from those observed in the
192 PCR- individuals or in the PPHC (Figure 5C and E). However, the frequencies of S-specific
193 memory B cells had substantially increased in the mild patients after 3 months (ranging from

194 0.17% to 0.64%; mean 0.35% during convalescence) and were comparable to frequencies
195 among severe patients. In addition, the levels were well maintained between 3 and 8
196 months in all groups (Figure 5E and F). Further phenotyping of the S-specific memory B cells
197 indicated that the majority of these cells may be specific for epitopes on S outside of the
198 RBD (Figure 5D). S-specific memory B cells in the circulation were predominantly IgG+, rather
199 than IgA+ (Figure 5D).
200
201 **The effect of vaccination on systemic and airway antibody levels**
202 We finally evaluated the influence of SARS-CoV-2 vaccination on the systemic and airway
203 antibody responses (Figure 6A). A subset of 20 individuals, 3 that recovered from mild, 9
204 from moderate and 8 from severe COVID-19 one year earlier, were sampled after receiving
205 their scheduled vaccination (range 270-407 days; median 339 days from symptom onset)
206 (Table 2). Donor-matched plasma, NSW and NPA were collected at different timepoints after
207 prime (7-16 days) from 18 patients and after boost (7-28 days) from 19 patients alongside
208 with samples from 12 individuals naïve to SARS-CoV-2 (7-10 days after prime and boost
209 vaccinations) to be included as a reference control. All samples were analyzed for the
210 presence of IgG and IgA against RBD. Antibodies against N were also measured in patient
211 plasma as a negative control as the vaccines used were based on the S protein. After
212 vaccination, all individuals demonstrated a significant increase of both plasma IgG and IgA
213 against the RBD (Figure 6B) but, as expected, not against N (Figure 6B). While the IgG levels
214 to RBD after boost vaccination exceeded the levels detected during the acute phase, the IgA
215 levels were equally high (Figure 6B). On the contrary, individuals naïve to SARS-CoV-2 only
216 had a moderate increase of IgA as compared with IgG after boost (Figure 6B). IgG levels after
217 boost were significantly lower in individuals naïve to SARS-CoV-2 as compared with those

218 from COVID-19 patients after boost (Figure 6C and Supplementary figure 5A). The airway IgG
219 levels to RBD also showed a noticeable increase after the boost vaccination in particular. In
220 fact, the IgG levels in the airway samples, both nasal swabs and NPA, were in many
221 individuals significantly higher after boost vaccination than they were in the acute stage of
222 the disease (Figure 6D). In contrast, this was not noted for IgA levels to RBD (Figure 6D). On
223 the other hand, individuals naïve to SARS-CoV-2 only had a modest but significant increase
224 of IgG in NSW and NPA and of IgA in NSW after boost (Figure 6D). Despite IgG levels in NSW
225 had the highest increase after boost in individuals naïve to SARS-CoV-2, levels were generally
226 significantly lower as compared with those from COVID-19 patients (Figure 6E and
227 Supplementary figure 5A).
228
229 **Discussion**
230 By now, it is well documented that higher systemic antibody levels are generated in severe
231 as compared with mild COVID-19 (7-11, 21-23). In contrast, the presence and durability of
232 antibodies against SARS-CoV-2 in the airways is much less understood. Nor is it known if and
233 how respiratory antibody levels are influenced by SARS-CoV-2 vaccination in humans. In this
234 study, we performed longitudinal analyses of systemic and upper and lower airway antibody
235 responses in a clinically well-characterized and relatively large cohort of individuals with
236 SARS-CoV-2 infection representing the full spectrum of COVID-19 severity ranging from
237 asymptomatic infection to fatal disease. Matched analyses in blood and in the airways
238 enabled us not only to address the magnitude and durability of systemic antibodies to SARS-
239 CoV-2 but also to gain insights into the prospects of protective capacity locally in the mucosa
240 at virus re-entry. This is one key aspect still largely unknown yet critical for our
241 understanding of immunity to and protection from SARS-CoV-2. Furthermore, we studied

242 how the systemic versus airway antibody levels were affected by vaccination. Collectively,
243 this data will contribute to a better understanding of long-term protective effects and
244 whether vaccination is important to boost the capacity of virus neutralization in the airways
245 and thus reducing re-infection and virus spread.
246
247 Airway mucus along the respiratory tract is thought to serve as a barrier that can trap
248 respiratory viruses via virus glycoprotein-mucin interactions (24). However, it has been
249 shown that local immobilization of respiratory viruses such as influenza viruses in the
250 airways mostly occurs by binding with virus-specific antibodies present in the mucus (25). As
251 the respiratory tract is the initial site of viral infection and replication, the levels of IgG and
252 IgA against the RBD in the upper and lower airways are likely critical for SARS-CoV-2
253 neutralization and could therefore help predict the ability of individuals to neutralize the
254 virus locally in case of re-exposure. Low but detectable levels of antibodies to SARS-CoV-2
255 have previously been reported in saliva during convalescence (26). However, measurements
256 of antibodies in saliva may primarily represent plasma exudate from the gingiva (27) while
257 respiratory secretions better reflect the mucosal responses. Sampling the respiratory
258 mucosa is indeed more likely to be sensitive to sampling methods compared to blood draws.
259 Ideally it is therefore important to sample multiple compartments to more comprehensively
260 understand the immunity to SARS-CoV-2. In our study we found that IgG and IgA against the
261 RBD can be readily detected in the upper and lower airways during acute disease and that
262 such levels correlated with the systemic response at the same time point and also followed
263 disease severity. However, for all the patients across disease severities, airway antibodies
264 waned to low levels much faster than those in plasma during convalescence. Whether these
265 low antibody levels observed at respiratory sites will be sufficient for preventing virus re-

266 entry or for protection is not known. The correlation between systemic and airway antibody
267 levels during acute disease raises questions on whether the low levels of antibodies in the
268 airways during convalescence are due to decreased antibody generation locally at mucosal
269 sites or are rather caused by decreased dissemination from the periphery once systemic
270 antibody levels start to wane. Antibodies in the upper respiratory tract have been shown to
271 be dominated by secretory IgA which are mostly produced by plasma cells in the lamina
272 propria of mucosa-associated lymphoid tissue (MALT) (28, 29). We detected high levels of
273 IgA in the upper airways early during acute COVID-19 that rapidly declined during
274 convalescence, following the pattern observed for systemic IgA levels here and in other
275 reports (30-32). This suggests that at least some IgA disseminated into the airways from the
276 circulation. In contrast, the dynamics of IgG were different in the respiratory samples
277 compared to plasma with airway IgG following the same kinetics as IgA, while systemic IgG
278 were well maintained up to 8 months.
279
280 When we assessed the presence of lymphocytes in the different airway compartments
281 during acute disease, we observed higher proportion of B cells along with high antibody
282 levels, especially IgA, in the nasopharynx, as compared with the nostril or the endotracheal
283 space. It has previously been shown that the majority of antibody secreting cells generated
284 after intranasal immunization with live-attenuated vaccines in rodents may reside in the
285 respiratory tract rather than in the spleen and bone marrow (33) and that these cells secrete
286 IgA early after a later challenge with the vaccination pathogen (34-36). Therefore, it is
287 possible that B cells generated during SARS-CoV-2 infection also reside locally in the airways
288 and contribute to antibody levels in the nasopharynx. While the antibody content in NPA
289 and ETA could be influenced by differences in sampling methods and sample volumes, these

290 data suggest that antibody abundance and possibly virus neutralization via IgA differ along
291 the respiratory tract and may be more pronounced in the nasopharynx compared to the
292 lower airways. Altogether, our observations demonstrate that moderate and severe COVID-
293 19 result in high levels of circulating antibodies and despite that IgG levels are well-
294 maintained, antibody levels in the airways decline significantly after the acute phase.
295
296 Once antibody titers have waned below protective levels, the response to a secondary
297 infection will mostly rely on the presence of resting antigen-specific memory B cells that can
298 rapidly activate upon antigen re-exposure (13). Therefore, similar to other studies (18-20),
299 we investigated the induction and maintenance of S-specific memory B cells. Importantly,
300 because of the comprehensive range of disease severity represented in our cohort, we were
301 able to compare the opposite ends of the COVID-19 disease spectrum by focusing on
302 individuals with mild disease as compared with patients with moderate/severe disease who
303 had the highest circulating IgG and IgA levels. Strikingly, despite the fact that these patients
304 were at the opposite ends of the disease severity spectrum, they had comparable levels of S-
305 specific memory B cells during convalescence. These appeared to be specific for epitopes on
306 S outside of the RBD and were predominantly IgG+, rather than IgA+, which may affect the
307 proportions of different isotypes subsequently produced in the event of antigen re-
308 exposure.
309
310 Immunization at mucosal sites such as for example intranasal administration of live-
311 attenuated influenza vaccines generally elicits mucosal immune responses (37). However,
312 several studies, primarily performed with DNA and virus-like particles (VLP) vaccines, have
313 shown that intradermal, subcutaneous and intramuscular immunization also can result in

314 local mucosal responses that protect from mucosal challenge (38). It has been speculated
315 that this could be due to free antigen or B cells migrating from the vaccine draining lymph
316 nodes to the MALT (38-40). A two-dose regimen of Moderna's mRNA-1273 vaccine
317 administered intramuscularly and followed by intranasal and intratracheal challenge with
318 SARS-CoV-2 in rhesus macaques has indeed shown to result in local virus neutralization in
319 the airways (41). Antibodies in bronchoalveolar lavage and nasal swabs were elicited in a
320 vaccine dose-dependent manner assessed after the boost vaccination (42).
321
322 Whether the systemic and/or mucosal immunity generated during natural infection is
323 boosted by vaccination and results in a similar or enhanced magnitude of responses would
324 be important knowledge to acquire for planning the best vaccination strategies for SARS-
325 CoV-2 as well as for other respiratory viruses. Our results on individuals recovering from
326 COVID-19 and subsequently receiving vaccination indicated a marked increase of both IgG
327 and IgA levels systemically but also strikingly in the airways, which in the majority of cases
328 exceeded the levels observed during acute disease. In contrast, vaccination of individuals
329 naïve to SARS-CoV-2 only resulted in a modest increase of airway antibodies, mainly IgG,
330 after boost vaccination. Notably, the antibody increase observed between prime and boost
331 vaccination in the patients was more prominent in the airways than systemically. Recent
332 studies on systemic antibody responses after SARS-CoV-2 vaccination in individuals who
333 recovered from COVID-19 have shown a significant increase in antibody levels after one
334 vaccine dose with no or only a small increase after the second dose (43-47). This suggests
335 that one vaccine dose may be sufficient to protect these individuals from disease in case of
336 re-infection which is important for vaccine dose management at the population level.
337 However, our data indicate that only assessing the systemic antibody levels after vaccination

338 is to some extent misleading as respiratory antibody levels, and likely virus neutralization,
339 may be substantially better with a prime-boost vaccination strategy rather than with one
340 single dose. Two earlier studies have been able to demonstrate neutralizing activity of
341 antibodies in the upper respiratory tract after vaccination in individuals who earlier had
342 COVID-19 (49, 50).
343
344 The higher levels of airway antibodies that we observed after two vaccine doses may be
345 explained by that even a small increase in circulating antibodies after the boost causes a
346 substantial extravasation from the bloodstream into mucosal sites (Supplementary figure
347 5B). On the other hand, the fact that naïve individuals had less pronounced airway
348 antibodies after vaccination despite they elicited relatively high plasma antibody levels
349 suggests that airway antibody responses are better primed with natural infection and that
350 vaccination after COVID-19 stimulates anamnestic local mucosal responses. It remains to be
351 investigated how airway antibodies induced after intranasal vaccination would compare to
352 natural infection and whether an intramuscular vaccine boost would affect these responses
353 (48).
354
355 In summary, here we show that COVID-19 disease severity not only determines the
356 magnitude of systemic but also airway antibody levels with efficient generation of virus-
357 specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma
358 IgG levels were generally well detectable after acute disease in all groups, there was a
359 significant decline in airway antibodies during convalescence. This suggests that antibodies
360 in the airways may not be maintained at levels that prevent local virus entry upon re-
361 exposure. However, our data indicate that the majority of infected individuals have the

362 ability to generate anamnestic responses via the memory B cell pool and that vaccination
363 against SARS-Cov-2 resulted in a substantial rebound of both systemic and airway antibodies
364 in patient who recovered from COVID-19. These data indicate a positive effect of vaccination
365 for increased virus neutralization in the airways and prospects of reduced virus spread,
366 which further supports following the full vaccination schedule also in this population.
367

368 **Methods**

369 **Study design, patient enrollment and sample collection**

370 One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were
371 enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut),
372 Stockholm, Sweden during March-May 2020 (acute phase) in a time that ranged from 0 to
373 54 days from onset of symptoms as self-reported by individual patients; and during April-
374 September 2020 (3 months) in a time that ranged from 46 to 168 days and during November
375 2020 to February 2021 (8 months) continuing from the previous counts. Patients were
376 enrolled at various settings, ranging from primary to intensive care. In order to recruit
377 asymptomatic and mild cases, household contacts of COVID-19 patients were enrolled and
378 screened with PCR to identify SARS-CoV-2 positive individuals. A small subset of these
379 individuals who experienced influenza-like symptoms and were possibly exposed to SARS-
380 Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of
381 confirmed patients with 1 experiencing fever, and 6 were included based on suspected
382 infection with 4 experiencing fever) were sampled in the same way and included as controls
383 alongside with 30 pre-pandemic healthy control samples (PPHC) from 2016-2018. Twelve
384 individuals naïve to SARS-CoV-2 were also recruited at the Umeå University, Umeå, Sweden
385 as a control group for vaccination (Table 2). These individuals were identified as naïve to

386 SARS-CoV-2 based on lack of COVID-19 symptoms and positive diagnostic PCR test
387 throughout the pandemic in combination with absence of plasma antibodies against SARS-
388 CoV-2 prior to vaccination.
389
390 Respiratory failure was categorized daily according to the respiratory domain of the
391 Sequential Organ Failure Assessment score (SOFA) (14). The modified SOFA score (mSOFA)
392 was calculated when arterial partial pressure of oxygen (PaO_2) was not available. In this case
393 peripheral transcutaneous hemoglobin saturation (SpO_2) was used instead (15). Estimation
394 of the fraction of inspired oxygen (FiO_2) based on O_2 flow was calculated as per the Swedish
395 Intensive Care register definition (51). Patients were categorized based on the peak
396 respiratory SOFA or mSOFA value with the 4-point respiratory SOFA score being extended
397 with additional levels to distinguish between admitted and non-admitted mild cases (both
398 respiratory SOFA score 0) and to include fatal outcome. Ten (10) patients with fatal outcome
399 had peak disease severity score 6 prior to death and 2 patients had scores of 4 and 5. For
400 convenience, the resulting 7-point composite peak disease severity (PDS) was condensed
401 into a broader classification consisting of mild (1-2), moderate (3-4), severe (5-6), and fatal
402 (7). Demographics and additional data were collected from medical records, including
403 clinical history and risk factors such as BMI and co-morbidities. Total burden of comorbidities
404 was assessed using the Charlson co-morbidity index (CCI) (52) (Table 1). Additional clinical
405 information on this patient cohort including the modulation of disease from time to study
406 inclusion to peak severity can be found in Falck-Jones et al (16).
407
408 Blood was collected in EDTA-containing tubes from all patients except those admitted to the
409 intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes

410 discarded in the last 12 hours. For some ICU patients, additional venous blood was also
411 collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were
412 collected from the majority of the patients whereas endotracheal aspirates (ETA) were only
413 collected from patients with mechanical ventilation intubated in the ICU. Admitted patients
414 were sampled during acute disease at up to four timepoints and ICU patient material was
415 collected up to ten timepoints. For this study, unless otherwise stated, the measurements
416 referring to acute disease were performed with samples collected at the time of study
417 inclusion and when patients returned for their follow-up visits at 3 and 8 months from
418 symptom onset. At follow-up sampling, all study individuals had been discharged (if
419 hospitalized) from the infectious diseases ward but some individuals (<10) who recovered
420 from severe COVID-19 were still in a hospital aftercare ward at the first follow-up sampling.
421 All study participants were confirmed SARS-CoV-2 negative by PCR at the time of follow-up
422 sampling, with the exception of 5 individuals who were PCR+ but with high Ct values (>34).
423

424 **Enzyme-linked immunosorbent assay (ELISA)**

425 The presence of IgG or IgA binding against the SARS-CoV-2 Nucleocapsid (N) and Spike (S)
426 trimer or the Receptor Binding Domain (RBD) monomer (5, 6) in plasma and airway samples
427 was assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant proteins were
428 received through the global health-vaccine accelerator platforms (GH-VAP) funded by the
429 Bill & Melinda Gates Foundation, Seattle, WA, USA. Briefly, 96-half well plates were coated
430 with 50ng/well of the respective protein. Plates were incubated with a selected duplicate
431 dilution that did not provide background noise against ovalbumin used as a negative control
432 (data not shown) (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5%
433 milk/PBS buffer). Duplicate 7-point serial dilutions were initially performed for measuring

434 plasma IgG against RBD during acute disease and after vaccination. The half maximal
435 effective concentration (EC_{50}) or the endpoint titer (dilution at the set OD value of 0.1) were
436 calculated using GraphPad Prism 9. The relation between EC50 and endpoint titer for these
437 samples is shown in Supplementary figure 5C. However, since for several samples with low
438 antibody concentration (mostly from the asymptomatic/mild category) the EC50 was below
439 the highest dilution used (of 1:20) and therefore below the limit of detection
440 (Supplementary figure 6A), the maximal optical density (OD) at 1:20 dilution was used for
441 most of the analyses. The relation between maximal OD and EC50 was verified in a subset of
442 patients with high IgG and IgA against S (Supplementary figure 6B). To be able to compare
443 pre- and post-vaccination antibody levels that would, in some instances, fall below and
444 above the lower and upper limits of detection, the endpoint titer was used instead.
445 Detection was performed with mouse and goat anti-human IgG or IgA HRP-conjugated
446 secondary antibodies (clone G18-145 from BD Biosciences and polyclonal from
447 ThermoFisher, respectively) followed by incubation with TMB substrate (BioLegend) which
448 was stopped with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and
449 washing with 0.1% Tween-20/PBS buffer were performed between each step. Absorbance
450 was read at 450nm and background correction at 550nm using an ELISA reader. Data were
451 reported as maximal absorbance i.e. OD, as stated above, and plotted using GraphPad Prism
452 9. All of the antibody measurements in plasma and respiratory samples from SARS-CoV-2
453 patients were run alongside with samples from two different control groups as described
454 above. Interestingly, low but readily detectable IgA reactivity against S was detected in the
455 pre-pandemic healthy controls and in the PCR- individuals (Supplementary figure 6C). After
456 having verified the specificity and sensitivity of our ELISA assay for IgA detection with
457 limiting sample dilutions (Supplementary figure 6D-E), we hypothesize that this might be due

458 to cross-reactivity on the shared portions of the S protein between SARS-CoV-2 and other
459 common cold coronaviruses. Reports have shown that cross-reactivity between
460 coronaviruses exists (53, 54).
461
462 **Flow cytometry**
463 Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged
464 at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was
465 removed using a 70 μm cell strainer and cells were subsequently stained with the
466 appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in
467 Figure 5A and in Table 3A. Staining of PBMC was performed on previously cryopreserved
468 samples. The appropriate combination of fluorescently labelled monoclonal antibodies
469 binding to different cell surface markers and with fluorescently labelled S and RBD proteins
470 used as probes for antigen-specific B cells is illustrated in Figure 5C and in Table 3B. Probes
471 were prepared from biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-
472 labelled streptavidin) considering the molecular weight of protein monomers and of the
473 streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for
474 S and with BV421 for the RBD. The gating strategy for the identification of antigen-specific
475 memory B cells is shown in Figure 5C. Briefly, after identification of lymphocytes in single
476 suspension, live B cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From
477 this gate, B cells were further isolated by expression of CD19 and CD20 and then switched
478 memory B cells were identified as IgD-IgM-. From these, S-specific switched memory B cells
479 were identified by binding to both S protein probes. Further characterization was then
480 carried out by analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror
481 IgD-IgM-IgG- B cells) and fluorescently labelled RBD. Stained cells from airway samples were

482 acquired using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria
483 Fusion both interfaced with the BD FACSDiva Software. Results were analyzed using BD
484 FlowJo version 10.
485
486 **Statistics**
487 Spearman correlation was used to assess the interdependence of 2 different non-categorical
488 parameters across individuals whereas Wilcoxon matched-pairs signed rank or Mann–
489 Whitney U tests as appropriate, were used to assess differences or similarities for one single
490 parameter between 2 different groups. Kruskal -Wallis with Dunn's multiple comparisons
491 test was used when assessing comparison between multiple groups. All of the above
492 statistical analyses were performed using GraphPad Prism 9.
493
494 The effect of disease severity on the acute response was estimated using linear regression.
495 We estimated both unadjusted models, as well as models adjusted for age, gender, days
496 from onset of symptoms and CCI (Charlson Comorbidity Index). The longitudinal models
497 using splines were estimated using multivariate multiple regression. The splines used were
498 linear, with knots placed on days 15 and 50. The location of the knots was chosen based on
499 visual inspection of the data, aided by kernel smoothing. The effect on standard deviations
500 from repeated measures was not adjusted for, as the primary focus of the longitudinal
501 analysis was description rather than statistical testing. Analysis was done in R, version 4.1.0
502 (R Core Team (2021). R: A language and environment for statistical computing. R Foundation
503 for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.)
504 When not stated otherwise, p-values smaller than 0.05 were considered statistically
505 significant.

506 **Study approval**

507 The study was approved by the Swedish Ethical Review Authority, and performed according
508 to the Declaration of Helsinki. Written informed consent was obtained from all patients and
509 controls. For sedated patients, the denoted primary contact was contacted and asked about
510 the presumed will of the patient and to give initial oral and subsequently signed written
511 consent. When applicable, retrospective written consent was obtained from patients with
512 non-fatal outcomes.

513

514 **Author contributions**

515 Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J.,
516 J.A., J.S., A.F. and M.F. Acquisition and sample processing: A.C., M.Y., S. F-J., S.V., B.Ö., E.Å.,
517 L.A., R.F-J., M.Ö., F.G., J.S., M. E. J.M. and C.A. Generation of data: A.C., M.Y., S. F-J., S.V., L.A.
518 and P.C.G. Provision of custom reagents: D.P., M.M., L.C., and N.P.K. Analysis and
519 interpretation of data: A.C., Ka.L. and A.S-S. Critical revision of the manuscript: all authors.
520 Statistical analysis: A.C., A.W., K.L. and S.O. Ka.L. and A.S-S. contributed equally to the study.

521

522 **Acknowledgments**

523 We thank the patients and healthy volunteers who have contributed to this study. We would
524 also like to thank Alicia Edin, Andy Dernstedt, Mikaela Lagerkvist, Emma Stenlund, Maj
525 Järner, medical students and hospital staff for assistance with patient sampling, collection of
526 clinical data and sample processing, the Biomedicum BSL3 core facility, Karolinska Institutet
527 and Fredrika Hellgren for assistance with English editing. This work was supported by grants
528 from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda

Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.

532 **References**

533

534 1. Gandhi RT, Lynch JB, and Del Rio C. Mild or Moderate Covid-19. *N Engl J Med.*
535 2020;383(18):1757-66.

536 2. Berlin DA, Gulick RM, and Martinez FJ. Severe Covid-19. *N Engl J Med.*
537 2020;383(25):2451-60.

538 3. Brodin P. Immune determinants of COVID-19 disease presentation and severity. *Nat*
539 *Med.* 2021;27(1):28-33.

540 4. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The
541 implications of silent transmission for the control of COVID-19 outbreaks. *Proc Natl*
542 *Acad Sci U S A.* 2020.

543 5. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, and Veesler D. Structure,
544 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.*
545 2020;181(2):281-92 e6.

546 6. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM
547 structure of the 2019-nCoV spike in the prefusion conformation. *Science.*
548 2020;367(6483):1260-3.

549 7. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of
550 antibody immunity to SARS-CoV-2. *Nature.* 2021;591(7851):639-44.

551 8. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early
552 Serological Signatures Track with SARS-CoV-2 Survival. *Immunity.* 2020;53(3):524-32
553 e4.

554 9. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et
555 al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med.*
556 2020;383(18):1724-34.
557 10. Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, et al. SARS-CoV-2
558 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. *mBio.*
559 2021;12(1):e02940-20.
560 11. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2
561 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis.* 2020;71(16):2027-
562 34.
563 12. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al.
564 Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-
565 Binding Domain by Structure-Guided High-Resolution Serology. *Cell.* 2020.
566 13. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, and Sallusto F. Dissecting the
567 human immunologic memory for pathogens. *Immunol Rev.* 2011;240(1):40-51.
568 14. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The
569 SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
570 dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of
571 the European Society of Intensive Care Medicine. *Intensive Care Med.*
572 1996;22(7):707-10.
573 15. Grissom CK, Brown SM, Kuttler KG, Boltax JP, Jones J, Jephson AR, et al. A modified
574 sequential organ failure assessment score for critical care triage. *Disaster Med Public*
575 *Health Prep.* 2010;4(4):277-84.

576 16. Falck-Jones S, Vangeti S, Yu M, Falck-Jones R, Cagigi A, Badolati I, et al. Functional
577 monocytic myeloid-derived suppressor cells increase in blood but not airways and
578 predict COVID-19 severity. *J Clin Invest.* 2021;131(6).
579 17. Hansen CB, Jarlhelt I, Perez-Alos L, Hummelshoj Landsy L, Loftager M, Rosbjerg A, et
580 al. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19
581 Convalescent Individuals. *J Immunol.* 2020.
582 18. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory
583 to SARS-CoV-2 assessed for up to 8 months after infection. *Science.* 2021.
584 19. Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al.
585 Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell.*
586 2021;184(1):169-83 e17.
587 20. Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and
588 circulating follicular helper T cell responses in recovered patients with COVID-19. *Nat*
589 *Med.* 2020.
590 21. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et
591 al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and
592 Associations with Age and Disease Severity. *Cell.* 2020.
593 22. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al.
594 Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship
595 to disease severity. *Clin Infect Dis.* 2020.
596 23. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent
597 antibody responses to SARS-CoV-2 in convalescent individuals. *Nature.* 2020.
598 24. Fahy JV, and Dickey BF. Airway mucus function and dysfunction. *N Engl J Med.*
599 2010;363(23):2233-47.

600 25. Wang YY, Harit D, Subramani DB, Arora H, Kumar PA, and Lai SK. Influenza-binding
601 antibodies immobilise influenza viruses in fresh human airway mucus. *Eur Respir J.*
602 2017;49(1).
603 26. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and
604 saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci*
605 *Immunol.* 2020;5(52).
606 27. Subbarao KC, Nattuthurai GS, Sundararajan SK, Sujith I, Joseph J, and Syedshah YP.
607 Gingival Crevicular Fluid: An Overview. *J Pharm Bioallied Sci.* 2019;11(Suppl 2):S135-
608 S9.
609 28. Reynolds HY. Immunoglobulin G and its function in the human respiratory tract.
610 *Mayo Clin Proc.* 1988;63(2):161-74.
611 29. Pakkanen SH, Kantele JM, Moldoveanu Z, Hedges S, Hakkinen M, Mestecky J, et al.
612 Expression of homing receptors on IgA1 and IgA2 plasmablasts in blood reflects
613 differential distribution of IgA1 and IgA2 in various body fluids. *Clin Vaccine Immunol.*
614 2010;17(3):393-401.
615 30. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the
616 early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med.* 2020.
617 31. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al.
618 Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus
619 severe COVID-19. *J Allergy Clin Immunol.* 2020.
620 32. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. Dynamics of
621 IgG seroconversion and pathophysiology of COVID-19 infections. *medRxiv.* 2020.

622 33. Sealy R, Webby RJ, Crumpton JC, and Hurwitz JL. Differential localization and function
623 of antibody-forming cells responsive to inactivated or live-attenuated influenza virus
624 vaccines. *Int Immunol.* 2013;25(3):183-95.
625 34. Rudraraju R, Surman S, Jones B, Sealy R, Woodland DL, and Hurwitz JL. Phenotypes
626 and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T
627 cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the
628 gut. *Virology.* 2011;410(2):429-36.
629 35. Surman SL, Rudraraju R, Sealy R, Jones B, and Hurwitz JL. Vitamin A deficiency
630 disrupts vaccine-induced antibody-forming cells and the balance of IgA/IgG isotypes
631 in the upper and lower respiratory tract. *Viral Immunol.* 2012;25(4):341-4.
632 36. Surman SL, Jones BG, Sealy RE, Rudraraju R, and Hurwitz JL. Oral retinyl palmitate or
633 retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus
634 vaccine in vitamin A deficient mice. *Vaccine.* 2014;32(22):2521-4.
635 37. Krammer F. The human antibody response to influenza A virus infection and
636 vaccination. *Nat Rev Immunol.* 2019;19(6):383-97.
637 38. Su F, Patel GB, Hu S, and Chen W. Induction of mucosal immunity through systemic
638 immunization: Phantom or reality? *Hum Vaccin Immunother.* 2016;12(4):1070-9.
639 39. Or-Guil M, Wittenbrink N, Weiser AA, and Schuchhardt J. Recirculation of germinal
640 center B cells: a multilevel selection strategy for antibody maturation. *Immunol Rev.*
641 2007;216:130-41.
642 40. Lycke NY, and Bemark M. The regulation of gut mucosal IgA B-cell responses: recent
643 developments. *Mucosal Immunol.* 2017;10(6):1361-74.

644 41. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al.
645 Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N*
646 *Engl J Med.* 2020;383(16):1544-55.
647 42. Corbett KS, Nason MC, Flach B, Gagne M, O' Connell S, Johnston TS, et al. Immune
648 Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection
649 in Nonhuman Primates. *bioRxiv.* 2021:2021.04.20.440647.
650 43. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al.
651 Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA
652 Vaccine. *N Engl J Med.* 2021;384(14):1372-4.
653 44. Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, et al.
654 Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care
655 Workers Previously Infected With SARS-CoV-2. *JAMA.* 2021;325(14):1467-9.
656 45. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct
657 antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals
658 following mRNA vaccination. *Sci Immunol.* 2021;6(58).
659 46. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, et al. A cautionary note
660 on recall vaccination in ex-COVID-19 subjects. *medRxiv.* 2021:2021.02.01.21250923.
661 47. Samanovic MI, Cornelius AR, Wilson JP, Karmacharya T, Gray-Gaillard SL, Allen JR, et
662 al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in
663 SARS-CoV-2-experienced individuals. *medRxiv.* 2021:2021.02.07.21251311.
664 48. Lund FE, and Randall TD. Scent of a vaccine. *Science.* 2021;373(6553):397-9.
665 49. Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al.
666 Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing
667 antibodies. *Nat Med.* 2021.

668 50. Mades A, Chellamathu P, Lopez L, Kojima N, MacMullan MA, Denny N, et al.
669 Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper
670 respiratory tract specimens following COVID-19 mRNA vaccination. *medRxiv.*
671 2021:2021.05.06.21256403.
672 51. Intensivvårdsregistret S. SIR:s riktlinje för registrering av SOFA. .
673 https://www.icuregswe.org/globalassets/riktlinjer/sofa.pdf.
674 52. Charlson ME, Pompei P, Ales KL, and MacKenzie CR. A new method of classifying
675 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic*
676 *Dis.* 1987;40(5):373-83.
677 53. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets
678 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
679 and Unexposed Individuals. *Cell.* 2020;181(7):1489-501 e15.
680 54. Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. Cross-reactive
681 serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic
682 coronavirus infection. *bioRxiv.* 2020.
683
684
685

686 **Table 1.** Clinical characterization of the SARS-CoV-2 infected cohort

Peak disease severity	1	2	3	4	5*	6*	7
Resp. SOFA score	0	0	1	2	3	4	
Admitted (Y/N)	N	Y	Y	Y	Y	Y	Y
PFI (kPa) **SFI**	> 53 > 400	> 53 > 400	< 53 ≤ 400	< 40 ≤ 315	< 27 ≤ 235	< 13 < 150	-
No. of individuals (%)	13 (8.8)	6 (4.1)	10 (6.8)	48 (33)	19 (13)	39 (27)	12 (8.2)
Age, mean (Range)	44 (24-72)	60 (41-72)	56 (46-78)	55 (24-76)	57 (42-74)	61 (25-77)	66 (52-78)
Male (%)	5 (38)	2 (33)	6 (60)	38 (79)	15 (79)	34 (87)	9 (75)
Days from symptoms to admission – median (Range)	-	10 (0-14)	8.5 (4-14)	10 (3-21)	7 (2-14)	10 (2-35)	7 (1-28)
Days from symptoms to inclusion "Acute" – median (Range)	9 (3-44)	11 (0-20)	13.5 (6-18)	13 (4-32)	21 (5-40)	22 (7-54)	13 (8-44)
Days from symptoms to 3-Mo follow-up – median (Range)	102 (88-136)	99,5 (82-103)	112 (81-127)	109 (46-155)	109 (48-130)	120 (53-168)	-
Days from symptoms to 8-Mo follow-up – median (Range)	232 (187-264)	238 (212-250)	245 (227-303)	247 (233-314)	241 (220-270)	254 (224-344)	-
VL (Ct value) median (Range)	27.5 (40-14)	25.0 (29-14)	26.7 (36-15)	26.8 (36-12)	25.8 (36-19)	24.0 (37-14)	20.5 (32-13)
CCI, mean (SD)	1 (2)	2 (1)	1 (1)	2 (2)	2 (1)	2 (1)	3 (1)
BMI, mean (SD)	24.1 (4.5)	25.1 (2.2)	26.0 (3.2)	30.3 (4.2)	29.2 (5.3)	28.6 (4.7)	28.6 (2.4)
Hypertension (%)	1 (8.3)	0 (0)	2 (20)	20 (42)	8 (42)	15 (38)	9 (75)
Diabetes (%)	2 (17)	0 (0)	1 (10)	14 (29)	5 (26)	9 (23)	3 (25)
Current smokers (%)	0 (0)	0 (0)	2 (20)	5 (11)	1 (5.3)	2 (5.3)	0 (0)
ACE-I (%)	0 (0)	0 (0)	0 (0)	5 (10)	1 (5.3)	4 (10)	1 (9.1)
IS drugs (%)	1 (7.7)	0 (0)	0 (0)	4 (8.3)	2 (11)	5 (13)	1 (8.3)

687 Peak disease severity: 1-2 (Mild), 3-4 (Moderate), 5-6 (Severe), 7 (Fatal)
688 Resp. SOFA: Respiratory Sequential Organ Failure Assessment
689 PFI: PaO_2/FiO_2-index
690 SFI: SpO_2/FiO_2-index
691 VL: Viral Load
692 CCI: Charlson comorbidity index
693 BMI: body mass index
694 ACE-I: angiotensin converting enzyme-inhibitors
695 IS: immunosuppressive
696 *Requires mechanical ventilation
697

698 **Table 2.** Peak disease severity and longitudinal sampling timeline of patients and individuals

699 naïve to SARS-CoV-2 vaccinated against SARS-CoV-2.

PDS	Acute*	3 Mo*	8 Mo*	Vax*	Prime**	Boost**	Vaccine
1	24	129	240	338	7		AstraZeneca
1	9	113	266	308	7	7	AstraZeneca
1	7	92	128	350	7	7	Moderna
3	15	90	250	358	7	7	AstraZeneca
3	14	127	238	322	11	7	AstraZeneca
4	10	100	254	345	16	13	Pfizer–BioNTech
4	23	84	252	339	9	13	AstraZeneca
4	12	153	244	407	7	7	Moderna
4	16	138	245	426	7	7	Pfizer–BioNTech
4	16	106	237	399	7	7	Pfizer–BioNTech
4	28	134	257	386	7	7	Pfizer–BioNTech
4	18	102	NS	355	7	7	Pfizer–BioNTech
5	24	109	231	340	7	7	Moderna
6	22	98	244	329	8	8	Pfizer–BioNTech
6	34	139	260	308	NS	7	Pfizer–BioNTech
6	38	144	301	324	14	28	Pfizer–BioNTech
6	43	142	254	339	11	13	Pfizer–BioNTech
6	21	124	226	270	NS	21	Pfizer–BioNTech
6	30	92	NS	286	8	10	Moderna
6	8	86	262	407	7	7	Moderna
0	NA	NA	NA	NA	9	9	Moderna
0	NA	NA	NA	NA	10	6	Moderna
0	NA	NA	NA	NA	9	9	Moderna
0	NA	NA	NA	NA	9	9	Moderna
0	NA	NA	NA	NA	9	9	Moderna
0	NA	NA	NA	NA	9	8	Moderna
0	NA	NA	NA	NA	9	9	Moderna
0	NA	NA	NA	NA	9	8	Moderna
0	NA	NA	NA	NA	9	7	Pfizer–BioNTech
0	NA	NA	NA	NA	8	7	Pfizer–BioNTech
0	NA	NA	NA	NA	8	7	Pfizer–BioNTech
0	NA	NA	NA	NA	7	7	Pfizer–BioNTech

700 PDS: Peak disease severity
701 M=male, F=female, O=other
702 NS=not sampled
703 NA=not applicable
704 *Days from onset of symptoms
705 **Days from prime/boost

AstraZeneca (Vaxzevria)
Pfizer-BioNTec (Comirnaty)
Moderna (mRNA-1273)

710 **Table 3.** Flow cytometry panels.
711
712
713 **A)** Immunophenotyping of leukocyte subsets in airway samples.
714

Fluorochrome	Marker	Company	Cat. No.	Clone
PerCP-Cy5.5	CD3	BD	552852	SP34-2
FITC	CD56	BioLegend	318304	HCD56
PE-Cy7	CD123	BD	560826	7G3
PE-Cy5	CD16	BD	555408	3G8
PE	Lox-1	BioLegend	358603	15C4
APC-Vio770	CD66	Miltenyi	130-119-847	TET2
Alexa Fluor 700	CD4	BD	560836	L200
APC	CD45	BD	555485	HI30
BV786	CD11c	BD	740966	B-ly6
BV650	HLA-DR	BioLegend	307650	L243
BV510	CD14	BD	740187	SP34-2
Pacific Blue	CD19	Thermo Fisher	MHCD1928	SJ25-C1
(DAPI)	Live/Dead Blue	Thermo Fisher	L-23105	

715
716
717 **B)** Staining of circulating antigen-specific memory B cells.
718

Fluorochrome	Marker	Company	Cat. No.	Clone
PerCP-Cy5.5	IgM	BD	561285	G20-127
FITC	IgD	Southern Biotech	2030-02	Polyclonal
(PE-Cy5)	7AAD	Thermofisher	A1210	
ECD	CD19	Beckman Coulter	IM2708U	J3-119
PE	Spike			
Alexa Fluor 700	CD27	Biolegend	356416	M-T271
APC	Spike			
BV786	IgG	BD	564230	G18-145
BV605	CD20	BioLegend	302334	2H7
BV510	CD3	BD	740187	SP34-2
"	CD14	BioLegend	301842	M5E2
"	CD16	BD	563830	3G8
"	CD56	BD	740171	B159
BV421	RBD			

719

720



Figure 1. Study and sampling overview. (A) Overview of study cohort (n=147), timeline of longitudinal sampling, hospital admission/discharge, level of care and outcome for each patient. Patients are group based on peak disease severity (PDS); mild (PDS 1 and 2), moderate (PDS 3 and 4), severe (PDS 5 and 6) and fatal (PDS 7). Individual inclusion sample for each patient is color-coded based on disease severity at the time of sampling. **(B)** Overview of the anatomical compartments analyzed, and the measurements performed.



Figure 2. Systemic antibody responses, inflammation markers and other clinical parameters in relation to COVID-19 severity during acute disease. (A) Plasma IgG and IgA responses (n=19 for mild, n=58 for moderate, n=58 for severe and n=12 for fatal) against N, S and RBD are shown together with the levels of **(B)** C-reactive protein and the neutrophil-lymphocyte ratio as a measure of systemic inflammation and with **(C)** the levels of lymphocytes, monocytes and neutrophils. Black lines indicate medians. Differences were assessed using Kruskal -Wallis with Dunn's multiple comparisons test and considered statistically significant at $p<0.05$. ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$. The dashed lines indicate the normal thresholds or range values. **(D)** Correlation matrix summarizing the interrelationship observed between the clinical parameters, inflammation markers, blood corpuscles and data from systemic antibody levels measured during acute disease as indicated. The P and R values (Spearman) are shown separately in the mirrored halves of the matrix and have been color-coded as indicated.



Figure 3. Longitudinal systemic antibody responses across COVID-19 severity from acute disease up to 8 months from symptom onset. (A) Individual levels of plasma IgG and IgA (from left to right) in SARS-CoV-2 infected individuals (n=147) with different peak disease severity (PDS). Black lines indicate medians and dotted lines indicate the average background level from pre-pandemic healthy controls. Kruskal-Wallis with Dunn's multiple comparisons was used to compare the groups and considered statistically significant at $p<0.05$. ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$. **(B)** Splines graphs of the plasma RBD IgG and IgA level changes over time (n=19 for mild, n=58 for moderate, n=58 for severe and n=12 for fatal). All observations are graphed together with kernel smoothed curves and data points for each group color-coded as previously with the exception of the "Fatal" group which in this figure is highlighted in black. The bandwidth for the smoothing was set to 40, except for the "Fatal" group, for which, due to few and concentrated observations, the bandwidth was set to 10.



Figure 4. Longitudinal airway antibody responses to RBD across COVID-19 severity from acute disease up to 8 months from symptom onset. Levels of IgG and IgA to RBD in **(A)** nostrils swabs (NSW) and **(B)** nasopharyngeal aspirates (NPA). The black lines indicate median values. Kruskal-Wallis with Dunn's multiple comparisons was used to compare the groups and considered statistically significant at p<0.05. *p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. In A) the line overlaps with not detected (ND) for IgG levels. **(C)** Heat map generated grouping patients according to PDS showing acute and convalescent IgG and IgA titers against N, S and RBD (plasma) and RBC (NSW, NPA and ETA) for each patient. The heat map includes data from patients (n=147) and also data from PPHC (n=30) and PCR-individuals (n=9) (indicated with PDS 0). Missing data and not available samples are shown in black. **(D)** Comparison of the levels of RBD IgG/A in patient-matched NSW, NPA, endotracheal aspirates (ETA) and plasma collected at the same time point. The black lines connect data points from the same individuals. Friedman test with Dunn's multiple comparisons test was used to compare the groups and considered statistically significant at p<0.05. **** p<0.0001. **(E)** Spearman correlation for NPA (n=34) versus plasma immunoglobulins against the RBD during acute disease.



Figure 5. Assessment of frequencies of B cells in the respiratory tract and of circulating S-specific memory B cells. (A) Representative example with gating strategy for the identification of lymphocytes (identified as negative for CD14/16/123/66) and of total B cells (CD3-CD19+) in respiratory NPA and ETA samples. **(B)** Lymphocytes and total B cells in NPA and ETA in a subset of patients alongside with NPA from healthy controls. Kruskal-Wallis with Dunn's multiple comparisons test was used and considered statistically significant at $p<0.05$. ** $p<0.01$. **(C)** Representative examples with gating strategy of SARS-Cov-2 S-specific memory B cells from one pre-pandemic healthy control, 3-month follow-up samples from one SARS-CoV-2 PCR- individual and one mild and one moderate/severe COVID-19 patient. Further characterization of S-positive memory B cells on RBD binding and B cell isotype (IgG+ or IgA+ assumed to correspond to IgD-IgM-IgG- B cells). **(D)** Bar charts show the cumulative proportion (frequency) of Spike (blue) and RBD (yellow) specific memory B cell as well as the proportion of IgG (green) vs. IgA (red) isotypes among the Spike specific memory B cells in longitudinal samples from mild (n=6) and moderate/severe (n=8) COVID-19 patients. **(E)** Frequencies of S-specific memory B cells in matched acute (filled) and 3-month follow-up (filled with black lining) PBMCs in relation to days in the subset of individuals analyzed (n=14) color-coded according to PDS. Dotted lines on indicate the average background staining from PCR- and PPHC. **(F)** Levels of circulating Spike+ switched memory B cells during acute disease and convalesce in the subset of patients analyzed, as well as PPHC, color-coded according to PDS. Circles with black lining refer to data during the convalescent phase. Black triangles symbolize the PPHC. Differences were assessed using Kruskal -Wallis with Dunn's multiple comparisons test and considered statistically significant at $p<0.05$. ** $p<0.01$.



Figure 6. Vaccination and systemic and airway antibody level rebound. (A) Overview of vaccinated patients (n=20) with respect with peak disease severity during COVID-19 and sampling timeline after prime and boost as compared with vaccination in individuals naïve to SARS-CoV-2 (n=12). The anatomical compartments analyzed and the measurements performed are also shown. **(B)** Compiled patient-matched longitudinal data from acute, 3-month- and 8-month follow-ups are shown together with data from after prime and after boost for the levels of plasma IgG and IgA against N and RBD. **(C)** Direct comparison between plasma RBD IgG after boost in COVID-19 patients and individuals naïve to SARS-CoV-2. **(D)** Compiled data as above for RBD IgG and IgA in NSW and NPA. **(E)** Direct comparison between NSW RBD IgG after boost in COVID-19 patients and individuals naïve to SARS-CoV-2. The grey lines connect data points from the same individuals. Data are color-coded according to peak disease severity during COVID-19 with data from individuals naïve to SARS-CoV-2 shown in black as a comparison. Differences were assessed using Kruskal -Wallis with Dunn's multiple comparisons test and considered statistically significant at $p<0.05$. ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$.